FOLLOW UP OF THE ALPHA TOCOPHEROL, BETA CAROTENE LUNG

α 生育酚、β 胡萝卜素肺的随访

• 批准号: 3676456
• 负责人: JARMO VIRTAMO
• 金额: $ 40.15万
• 依托单位: NATIONAL INSTITUTE FOR HEALTH & WELFARE
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-09-30 至 2001-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3676456
• 关键词: cancer prevention; cancer risk; carotene; chemoprevention; clinical trials; human mortality; human subject; lung neoplasms; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer epidemiology; tocopherols; vitamin therapy

The proposed project is a continuation of a project initiated in Finland in 1984 as a collaboration between the U.S. National Cancer Institute and the National Public Health Institute of Finland. The main activity been the Alpha-Tocopherol Beta-Carotene Lung Cancer Prevention Study (ATBC Study), a large randomized, double-blind, placebo-controlled, 2x2 factorial design, primary prevention trial testing the effects of alpha-tocopherol and beta- carotene supplements on lung cancer incidence and mortality. The primary objective of the present project is to follow all living participants in the ATBC Study (N=24,000) during the post-intervention period (1994-2000) to continue to monitor potential intervention effects on lung and other cancers and other morbidity and mortality endpoints. It is plausible that the effects of intervention with such agents will continue several years beyond the immediate period of administration of active agents. Monitoring cancer rates as well as morbidity and mortality from noncancer causes in the post-intervention period will allow us to determine if such effects exist and how long they last. Cancer incidence and all causes of mortality will be determined throughout the proposed 7-year period. Periodic contact with the study population is planned (years 2 and 5) which will permit collection of updated risk factor information including additional biologic specimens in some subjects. Another objective is to study the existing risk factor data and biologic samples for cancer control and causation hypotheses. These data provide an invaluable resource for the study of biochemical and molecular hypotheses. Such analyses will be more informative with the additional cases identified during the continued followup. In summary, the ATBC Study is the largest lung cancer chemoprevention trial ever conducted. Developed and implemented over the pst 10 years, it is an invaluable resource for cancer prevention research. Further follow-up of the 25,000 living participants from this intervention study is of undeniable importance in the field of cancer prevention.

拟议的项目是 2017 年在芬兰启动的一个项目的延续。 1984 年，美国国家癌症研究所与 芬兰国家公共卫生研究所。 主要活动是 α-生育酚 β-胡萝卜素肺癌预防研究（ATBC 研究）， 大型随机、双盲、安慰剂对照、2x2 析因设计， 一级预防试验测试α-生育酚和β-生育酚的作用 胡萝卜素补充剂对肺癌发病率和死亡率的影响。 本项目的主要目标是跟踪所有生活 干预后 ATBC 研究的参与者 (N=24,000) 期间（1994-2000）继续监测潜在的干预影响 肺癌和其他癌症以及其他发病率和死亡率终点。 这是 此类药物的干预效果可能会持续下去 超过活性药物直接给药期数年 代理。 监测癌症发病率以及发病率和死亡率 干预后的非癌症原因将使我们能够确定 这种影响是否存在以及持续多久。 癌症发病率及所有 将在拟议的 7 年时间内确定死亡原因 时期。 计划与研究人群定期接触（第 2 年和 5) 这将允许收集更新的风险因素信息 包括某些受试者的额外生物样本。 另一个目标是研究现有的危险因素数据和生物制剂 用于癌症控制和因果假设的样本。 这些数据提供了 研究生化和分子假说的宝贵资源。 随着确定的其他案例的出现，此类分析将提供更多信息 在持续跟进的过程中。 总之，ATBC 研究是最大的肺癌化学预防试验 曾经进行过。 经过过去 10 年的开发和实施， 癌症预防研究的宝贵资源。 进一步跟进 这项干预研究的 25,000 名活着的参与者是 在癌症预防领域具有不可否认的重要性。